Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The saponin digitonin, the aglycone digitoxigenin and five cardiac glycosides were evaluated for cytotoxicity using primary cultures of tumor cells from patients and a human cell line panel (representing different cytotoxic drug-resistance patterns). Of these seven compounds, proscillaridin A was the most potent (IC(50): 6.4--76 nM), followed by digitoxin, and then ouabain, digoxin, lanatoside C, digitoxigenin and digitonin. Correlation analysis of the log IC(50) values for the cell lines in the panel showed that compound cytotoxicity was only slightly influenced by resistance mechanisms that involved P-glycoprotein, topoisomerase II, multidrug resistance-associated protein and glutathione-mediated drug resistance. Digitoxin and digoxin expressed selective toxicity against solid tumor cells from patients, while proscillaridin A expressed no selective toxicity against either solid or hematological tumor cells. The results revealed marked differences in cytotoxicity between the cardiac glycosides, both in potency and selectivity, and modes of action for cytotoxicity that differ from that of commonly used anticancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyd, M. R., & Paull, K. D. (1995) · Drug Development Research · doi:10.1002/ddr.430340203 · Cited by 1,572
Stein (2000) · doi:10.1054/mehy.1999.0985 · Cited by 171
Is digitalis a therapy for breast carcinoma?
Stenkvist, B. (1999) · Oncology Reports · doi:10.3892/or.6.3.493 · Cited by 160
Structure–cytotoxic activity relationship for the toad poison bufadienolides
Kamano, Y., Kotake, A., Hashima, H., Inoue, M., Morita, H., Takeya, K., Itokawa, H., Nandachi, N., Segawa, T., Yukita, A., et al. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00067-4 · Cited by 129
INADA, A., NAKANISHI, T., KONOSHIMA, T., KOZUKA, M., TOKUDA, H., NISHINO, H., & IWASHIMA, A. (1993) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.16.930 · Cited by 34
Cited by
Novel therapeutic applications of cardiac glycosides
Prassas, I., & Diamandis, E. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2682 · Cited by 673
Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity
Huh, J. R., Leung, M. W. L., Huang, P., Ryan, D. A., Krout, M. R., Malapaka, R. R. V., Chow, J., Manel, N., Ciofani, M., Kim, S. V., et al. (2011) · Nature · doi:10.1038/nature09978 · Cited by 536
Cardiac Glycosides as Novel Cancer Therapeutic Agents
Newman, R. A., Yang, P., Pawlus, A. D., & Block, K. I. (2008) · Molecular Interventions · doi:10.1124/mi.8.1.8 · Cited by 515
Meng, Z., Yang, P., Shen, Y., Bei, W., Zhang, Y., Ge, Y., Newman, R. A., Cohen, L., Liu, L., Thornton, B., et al. (2009) · Cancer · doi:10.1002/cncr.24602 · Cited by 289
Anticancer steroids: linking natural and semi-synthetic compounds
Salvador, J. A. R., Carvalho, J. F. S., Neves, M. A. C., Silvestre, S. M., Leitão, A. J., Silva, M. M. C., & Sá e Melo, M. L. (2013) · Nat. Prod. Rep. · doi:10.1039/c2np20082a · Cited by 276
Metadata
- Authors
- Johansson, S., Lindholm, P., Gullbo, J., Larsson, R., Bohlin, L., & Claeson, P.
- Venue
- Anti-Cancer Drugs
- Published
- 2001-06
- Volume
- 12
- Issue
- 5
- Pages
- 475-483
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W2041096933
- Cited by
- 121
- References
- 5
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. https://app.cochat.ai/papers/10.1097/00001813-200106000-00009
- The paper
- Johansson, S., Lindholm, P., Gullbo, J., Larsson, R., Bohlin, L., & Claeson, P. (2001). Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anti-Cancer Drugs. https://doi.org/10.1097/00001813-200106000-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.